The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.

le Kvols, L. K., Reubi, J. C., Horisberger, U., Moertel, C. G., Rubin, J., Charboneau, J. W.
Foilsithe 1992

A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors

le Strosberg, J. R., Weber, J. M., Choi, J., Campos, T. L., Valone, T. L., Han, G., Schell, M. J., Kvols, L. K.
Foilsithe in Ann Oncol (2012)

A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors

le Strosberg, J R, Chan, J A, Ryan, D P, Meyerhardt, J A, Fuchs, C S, Abrams, T, Regan, E, Brady, R, Weber, J, Campos, T, Kvols, L K, Kulke, M H
Foilsithe 2013